Compare Citius Pharmaceuticals Inc (CTXR) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Workiva Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Workiva Inc trades at $75.4 (market cap $4.01B). The key difference: Workiva Inc is far larger — about 294.4× Citius Pharmaceuticals Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Workiva Inc for 21 Days on average.
| CTXR | WK | |
|---|---|---|
Market Cap | $13.62M | $4.01B |
Volume | 132,438 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $1.82 | $93.31 |
52-Week Low | $0.48 | $44.31 |
Typical Hold Time | 16 Days | 21 Days |
Enterprise Value | $3.79M | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
WK trades at $71.53, up 1.95% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and analyst consensus of $86 price target. Revenue grew to $966M in 2026 with net income turning positive at $47M. Recent news highlights AI innovation and inclusion in major indices, supporting positive sentiment.
The outlook remains positive with 89% analyst buy ratings and improving profitability. Key risks include high valuation multiples (P/E 87.7) and competitive pressures in the regulatory software space. The stock offers growth potential but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
